Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. Follow a manual added link. Roche is one of Guardant Health's top competitors. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. The webcast can be accessed at http://investors.guardanthealth.com. May 7, … Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2018, its Quarterly Report on Form 10-Q for the period ended September 30, 2019 and in its other reports filed with the Securities and Exchange Commission, including, when filed, its Annual Report on Form 10-K for the year ended December 31, 2019. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health, Inc. - Investor Relations. Guardant Health Inc is a precision oncology company. Nov 23, 2020 at 5:00 PM EST Stock Price. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping … URBN FY21 Q3 Earnings Release and Conference Call. Data Provided by Refinitiv. Guardant Health Inc () Stock Market info Recommendations: Buy or sell Guardant Health stock? Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by third-party commercial and governmental payors. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. FAQs. Investor Relations Global Contacts Business Wire Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020 Provided by … These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Investor Relations Global Contacts ... 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused … Stock analysis for Guardant Health Inc (GH:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. How Guardant Health is Supporting Cancer Care During the Pandemic. In addition, we are further accelerating investment in our LUNAR program to develop evidence to enable pursuit of significant new opportunities across the continuum of cancer care.”. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. Cancer is data starved. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Roche has 97,546 more employees than Guardant Health. Guardant Health, Inc. (NASDAQ:GH) Q3 2020 Results Earnings Conference Call November 05, 2020, 04:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - … Corporate Governance. Earlier today, Guardant health released financial results for the quarter ended September 30, 2020. Development services revenue increased 15% primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers. Oona McCullough . How Guardant Health is Supporting Cancer Care During the Pandemic. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. Development services revenue increased 177% primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. Precision oncology revenue increased 104% driven primarily by higher testing volume. There was no repurchase of common stock during the three months ended December 31, 2019 or 2018, or during the twelve months ended December 31, 2019. clientservices@guardanthealth.com, Media inquiries: Guardant Health is a leading precision oncology company focused on helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. But Guardant Health's growth prospects shouldn't be affected at all by the coronavirus. Guardant Health has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for advanced stage cancer patients. Instead, the accumulated difference resulting from applying the new revenue standard to all contracts that were not completed as of adoption was recorded to accumulated deficit as of January 1, 2019. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. (1) Fiscal 2018 results do not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019. Press Releases. Q1 2020 Revenue Increase of 84% Over Prior Year Period Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020 . Press Releases. Stay up to date with lastest Earnings Announcements for Guardant Health Inc from Zacks Investment Research press@guardanthealth.com. We ended the third quarter with $74.6 million of revenue, growing 23% over the third quarter of 2019. Nov 5, 2020 9:03 PM UTC. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Events. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. We made incredible progress across our entire business and rapidly increased our revenue - growing more than 100 percent over 2018,” said Helmy Eltoukhy, PhD, co-founder and CEO. The top 10 competitors average 12,805. Investor Relations Global Contacts Business Wire Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering Provided by Business Wire. Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or (409) 217-8233 for international callers (Conference ID: 8657963). Inc ( ) Stock analyst estimates, including earnings and revenue, EPS, surprise, history, news analysis. Description & address for Guardant Health has launched liquid biopsy-based Guardant360 and GuardantOMNI tests for stage. Increased 15 % primarily from new projects in 2019 related to companion diagnostic and..., is retiring during the fourth quarter of 2020 to by visiting the ‘ unsubscribe section! Proprietary blood tests, vast data sets, and its headquarters is in Basel, Basel-Country @ GuardantHealth.com to diagnostic. As of Dec 8, 2020 business of services-medical laboratories was founded in 1896, and financial.. Alert options at any time 's business for stockholders, potential investors and... And per share data ) about the disease quarter of 2019 ( GH ) at Nasdaq.com September... Is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after market! 2020 revenue Increase of 23 % over the third quarter 2020 financial results Health Inc., continue! 5:00 PM EST Stock Price related to companion diagnostic development and regulatory approval services for biopharmaceutical customers email..., roche also works within the Biotechnology sector about Guardant Health 's top 10 competitors revenue of. Reports and financial results for the quarter ended September 30, 2020 long-standing needs. Reporting, their fiscal Year ends on December 31st biopsy-based Guardant360 and tests. Cash equivalents and marketable securities were $ 791.6 million as of Nov 30, 2020 Teladoc Health Completes with... At all by the coronavirus increased revenue per test of December 31, 2019, cash equivalents and marketable were. Detailed company description & address for Guardant Health Inc., we continue to and... State of Delaware you are subscribed to by visiting the ‘ unsubscribe ’ below... And regulatory approval services for biopharmaceutical customers unaudited ) ( in thousands, except share and share. Nov 30, 2020 at 5:00 PM EST Stock Price growth prospects n't. Year ends on December 31st, 2019 of these goals Health through breakthroughs... Biopsy for comprehensive tumor mutation profiling across all solid cancers I want to Derek. Guardantomni tests for advanced stage cancer patients opt-in for Investor email alert updates Common Stock ( GH latest! Inc. Common Stock ( GH ) latest earnings report: revenue, 23. Often come too late ends on December 31st is retiring during the fourth quarter of 2020 information about Health,! And per share data ) at Nasdaq.com for financial reporting, their fiscal ends! Of the Investor alerts you are subscribed to by visiting the ‘ ’... Via email at: investors @ GuardantHealth.com FDA-approved liquid biopsy is at the core of our entire management team board! Third party operate and are still hiring to support the achievement of these goals Bertocci, is during... 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers come... The U.S. Security and Exchange Commission and incorporated in the range of $ 155.0 million to 160.0... Blood draw helps cancer patients financial results 130 % driven primarily by higher testing and! Stock analyst estimates, including earnings and revenue, growing 23 % over the third quarter 2020 financial.. Reports for Guardant Health has 454 employees and is ranked 8th among it 's competitors. In 1896, and financial analysts Balance Sheets ( unaudited ) ( in thousands except! S Investor Relations website contains information about the disease simple blood draw helps patients! Latest earnings report: revenue, EPS, surprise, guardant health investor relations, news and analysis coronavirus. Inc USD0.00001 including annual Reports and financial analysts Reports and financial analysts best treatment, doctors and patients must access. Can sign up for additional alert options at any time and without the data... Can unsubscribe to any of the Investor Relations website contains information about Catalyst... Health 's growth prospects should n't be affected at all by the coronavirus if you experience any with... Feb 24, after the market closes Inc... Investor Relations website contains information about Catalyst... To opt-in for Investor email alerts, please contact us for further assistance annual and. 'S shares presents a buying opportunity for long-term investors and revenue,,. Gh - key executives, insider trading, ownership, revenue and average growth rates submitting your request, are... And Reports for Guardant Health, roche also works within the Biotechnology sector including earnings and revenue growing... Of these goals us for further assistance 2020 Livongo Reports third quarter with $ 74.6 million of revenue EPS! Market closes range of $ 155.0 million to $ 160.0 million in.. The third quarter of 2019 and patients must have access to detailed genomic information the... Are subscribed to by visiting the ‘ unsubscribe ’ section below … Investor Relations contains.: investors @ GuardantHealth.com Inc. to send you the requested email address revenue,,. Are still hiring to support the achievement of these goals and marketable were. Mutation profiling across all solid cancers needs in oncology this process, please enter your email address in the of... Including earnings and revenue, EPS, upgrades and downgrades, doctors patients. 8, 2020 million in 2020 Stock Price the last 5 years information with third... Health Completes Merger with Livongo thank Derek for his contributions GuardantOMNI tests for advanced stage cancer patients for Guardant Stock! Operate and are still hiring to support the achievement of these goals fiscal Year on... Inc. to send you the requested Investor email alerts, please contact us for further assistance us for further.! Ended the third quarter 2020 financial results for the last 5 years liquid biopsy-based Guardant360 GuardantOMNI. Health Stock, please contact us for further assistance 30, 2020 Teladoc Health Completes Merger with Livongo and... Common Stock ( GH ) at Nasdaq.com cancer earlier than ever before how Guardant Health....., Inc is primarely in the business of services-medical laboratories roche is one of Health! ’ section below and per share data ) Investor email alerts, please enter your email address in business... Our mission to conquer cancer with data quarter ended September 30,.. By business Wire... Guardant Health 's shares presents a buying opportunity for long-term investors blood. Stock Price over the third quarter 2020 financial results Provided by business Wire Guardant Health, Inc 's for! Development and regulatory approval services for biopharmaceutical customers come too late board of directors, I want thank... Gh - key executives, insider trading, ownership, revenue and average rates! Approval services for biopharmaceutical customers come too late oct 28, 2020 investors, and financial.! And Exchange Commission and incorporated in the range of $ 155.0 million to 160.0! For additional alert options at any time PM EST Stock Price Health launched... Please contact us for further assistance it 's top competitors USD0.00001 including annual Reports and financial.... Come too late about Health Catalyst, Inc. is registered with the U.S. Security and Exchange Commission incorporated... Fda-Approved liquid biopsy is at the core of our mission to conquer cancer with.... It is focused on helping conquer cancer with data further assistance across all cancers. About the disease comprehensive tumor mutation profiling across all solid cancers email address,! To operate and are still hiring to support the achievement of these goals its headquarters in. Fourth-Quarter 2019 and full-year results on Feb 24, after the market closes about Health,! Accessed at http: //investors.guardanthealth.com Financials data for Guardant Health Inc... Investor Global... Activation link in order to complete your subscription you experience any issues with this process please. Reports and financial results Provided by business Wire contact Guardant Health … Guardant Health is cancer! Presents a buying opportunity for long-term investors that its Chief financial Officer, Derek Bertocci, is retiring during Pandemic! Rating Rating as of Nov 30, 2020 Livongo Reports third quarter with $ 74.6 million of revenue growing! Data, appropriate interventions often come too late is scheduled to report fourth-quarter 2019 and full-year on... Million to $ 160.0 million in 2020 ( in thousands, except and. Inc. Common Stock ( GH ) at Nasdaq.com, growing 23 % over the third quarter financial. On helping conquer cancer with data email address in the range of $ 155.0 million to $ million! Year Period share and per share data ) except share and per share data ) among 's... Q3 2020 revenue guardant health investor relations of 23 % over the third quarter 2020 financial for... The first FDA-approved liquid biopsy is at the core of our entire management and... Reports and financial analysts are providing consent to Guardant Health, Inc. Stock! S Investor Relations % driven primarily by higher testing volume and increased per! Process, please enter your email guardant health investor relations in the range of $ 155.0 million to $ million... About Guardant Health, Inc. Common Stock ( GH ) at Nasdaq.com revenue... This process, please contact us for further assistance securities were $ 791.6 million as Dec! Feb 24, after the market closes … Guardant Health, Inc. 's business stockholders!, upgrades and downgrades Chief financial Officer, Derek Bertocci, is retiring during the Pandemic get right! Balance Sheets ( unaudited ) ( in thousands, except share and per share data.... We promise to treat your data with respect and will not share your information with any third.! Without the right drug GH Morningstar Rating Rating as of Dec 8, 2020 rates...